OverviewSuggest Edit

BeiGene is a clinical-stage biopharma company focused on discovering and developing targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.
TypePublic
Founded2010
HQChangping Qu, CN
Websitebeigene.com
Employee Ratings2.9
Overall CultureD-

Latest Updates

Employees (est.) (Jul 2021)5,400(+2%)
Job Openings1,183
Revenue (FY, 2020)$308.9 M(-27%)
Share Price (Sept 2021)$337.3(-1%)
Cybersecurity ratingAMore

Key People/Management at BeiGene

John V. Oyler

John V. Oyler

Co-Founder, Chairman and CEO
Xiaodong Wang

Xiaodong Wang

Director & Co-founder
Xiaobin Wu

Xiaobin Wu

President, Chief Operating Officer, and General Manager of China
Julia Wang

Julia Wang

Chief Financial Officer
Denise Dettore

Denise Dettore

VP, Human Resources, U.S. and EMEA, & Co-Lead Global HR
Christiane Langer

Christiane Langer

Head of Global Medical Affairs
Show more

BeiGene Office Locations

BeiGene has offices in Changping Qu, Guangzhou Shi, Suzhou Shi, Cambridge and in 4 other locations
Changping Qu, CN (HQ)
30 Science Park Road, Zhong-Guan-Cun Life Science Park
Suzhou Shi, CN
Sang Tian Jie, Wuzhong Qu
Basel, CH
Aeschengraben 27/21st floor
Basel, CH
Teichgässlein 9/5th Floor
Cambridge, MA, US
55 Cambridge Pkwy #700W
Emeryville, CA, US
1900 Powell St #820
Show all (11)

BeiGene Financials and Metrics

BeiGene Revenue

BeiGene's revenue was reported to be $308.87 m in FY, 2020
USD

Revenue (Q1, 2021)

605.9m

Gross profit (Q1, 2021)

573.2m

Gross profit margin (Q1, 2021), %

94.6%

Net income (Q1, 2021)

66.5m

EBIT (Q1, 2021)

70.2m

Market capitalization (9-Sept-2021)

31.8b

Closing stock price (9-Sept-2021)

337.3

Cash (31-Mar-2021)

1.9b

EV

30.3b
BeiGene's current market capitalization is $31.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1m238.4m198.2m428.2m308.9m

Cost of goods sold

5.0m28.7m71.2m70.7m

Gross profit

233.4m169.5m357.0m238.2m

Gross profit Margin, %

98%86%83%77%
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

677.0k393.0k220.2m32.5m52.8m54.2m77.8m243.3m50.1m52.1m65.6m91.1m605.9m

Cost of goods sold

1.9m4.6m6.3m8.7m15.3m17.8m20.1m14.1m32.7m

Gross profit

218.3m28.0m46.5m45.5m62.6m225.5m30.0m37.9m573.2m

Gross profit Margin, %

99%86%88%84%80%93%60%73%95%
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

87.5m239.6m712.9m618.0m1.4b

Accounts Receivable

104.6m29.4m41.1m70.9m60.4m

Prepaid Expenses

35.6m81.9m90.2m160.0m

Inventories

6.2m10.9m16.2m28.6m89.3m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(119.2m)(93.3m)(674.0m)(950.6m)(1.6b)

Depreciation and Amortization

4.8m10.4m18.6m31.8m

Inventories

(2.1m)(10.9m)(5.3m)(12.3m)(58.9m)

Accounts Payable

2.7m55.3m23.5m2.2m95.8m
USDQ1, 2016

Financial Leverage

1.1 x
Show all financial metrics

BeiGene Operating Metrics

FY, 2016

Patents Issued

8

Patents Pending

21
Show all operating metrics

BeiGene Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

BeiGene Online and Social Media Presence

Embed Graph

BeiGene Company Culture

  • Overall Culture

    D-

    53/100

  • CEO Rating

    B-

    74/100

  • Compensation

    C

    70/100

Learn more on Comparably

BeiGene News and Updates

Zhongchao Inc. Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai

SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, announced the on-going one-year joint project of leukemia diagnosis...

111, Inc. Enters into First-Ever Strategic Partnership with BeiGene

SHANGHAI, March 17, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced today it has entered into a strategic...

Can BeiGene Stock Rebound After A 10% Drop?

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a 10% drop over the last ten trading days, while it’s down 6% over the last five trading days, but we believe the stock, after the recent correction...

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth Novartis secures development and commercialization rights in North America, Europe, and Japan …

Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million upfront payment and is eligible to receive up to $500 million in potential development, regulatory, and sales milestone payments plus royalties on…

Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale

Chinese Biotech Firm Beigene to Raise $2.1 Billion in Share Sale
Show more

BeiGene Blogs

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma

BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma Content Import Fri, 07/09/2021 - 00:00 BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with R…

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) Content Import Wed, 07/07/2021 - 20:00 BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab …

China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following the previously approved squamous histology Tislelizumab receives its first approval in liver cancer in previously treated hepatocellular carcinoma CAMBRIDGE, Mass.

BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia

Third approval for BRUKINSA in China and second approval in WM worldwide CAMBRIDGE, Mass. & BEIJING --(BUSINESS WIRE)--Jun. 18, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announc…

BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer

BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer Content Import Thu, 06/17/2021 - 07:01 BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Canc…

BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

BRUKINSA demonstrated long-term clinical benefits and tolerability in patients with mantle cell lymphoma and chronic lymphocytic leukemia at extended follow-up of nearly three years Tislelizumab achieved deep and durable responses in classical Hodgkin’s lymphoma with a median progression-free
Show more

BeiGene Frequently Asked Questions

  • When was BeiGene founded?

    BeiGene was founded in 2010.

  • Who are BeiGene key executives?

    BeiGene's key executives are John V. Oyler, Xiaodong Wang and Xiaobin Wu.

  • How many employees does BeiGene have?

    BeiGene has 5,400 employees.

  • What is BeiGene revenue?

    Latest BeiGene annual revenue is $308.9 m.

  • What is BeiGene revenue per employee?

    Latest BeiGene revenue per employee is $57.2 k.

  • Who are BeiGene competitors?

    Competitors of BeiGene include Axcella Health, Elektrofi and SeraCare.

  • Where is BeiGene headquarters?

    BeiGene headquarters is located at 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Changping Qu.

  • Where are BeiGene offices?

    BeiGene has offices in Changping Qu, Guangzhou Shi, Suzhou Shi, Cambridge and in 4 other locations.

  • How many offices does BeiGene have?

    BeiGene has 11 offices.